BioSpace News Archive

Takeda, Zedira and Dr. Falk Pharma will collaborate to develop ZED1227/TAK-227, a potential first-in-class investigational therapy for the treatment of celiac disease, Takeda announced Thursday.

Median Technologies (Euronext Growth - ALMDT) (Paris:ALMDT), whose Board of Directors approved on October 18, 2022 the consolidated IFRS financial statements for the first half of 2022 after a limited review, announces today its half-year results as well as revenues for the third quarter of 2022.

A Canadian startup that has created a digital assessment tool for monitoring Parkinson’s disease symptoms has won the 2022 AGE-WELL National Impact Challenge.

Using its extensive experience gained fighting COVID-19 and other virus threats for over 20 years, Integral Molecular has launched an expanded collection of its Reporter Virus Particles (RVPs) that offer a safe and rapid method to study some of the most virulent pathogens including influenza, Ebola virus, and SARS-CoV-2.

The global Embolotherapy market gathered revenue around USD 2.1 Billion in 2020 and market is set to grow USD 7.0 Billion by the end of 2027 and is estimated to expand at a modest CAGR of 9.0% during the prediction period 2021 to 2027.

Beyond Air, Inc. and, through its affiliate Beyond Cancer, Ltd. announced that it will report financial results for its second fiscal quarter ended September 30, 2022 on Tuesday, November 8, 2022.

Inhibrx, Inc., a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced it will be presenting at multiple upcoming scientific conferences.

HMNC Brain Health, a clinical stage biopharma company pioneering precision psychiatry, announced it has raised an additional EUR 14.3 million in a funding series, bringing the total capital raised to date to EUR 42.3 million.

Eyenovia, Inc. (NASDAQ: EYEN) today announced positive results from its VISION-2 Phase 3 study of MicroLine as a potential topical, on-demand treatment for presbyopia.

Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that it will report third quarter 2022 financial results after the market closes on Thursday, November 3, 2022.